SCHEMBL13623005

SCHEMBL13623005

CC(C)(C)OC(=O)Nc1cccc(CNC(=O)c2cccc(N)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 7/20 0.52
SENP2 Q9HC62 2/20 0.52
SENP5 Q96HI0 1/20 0.52
AURKA O14965 1/20 0.50
RPS6KB1 P23443 1/20 0.50
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
MMP13 P45452 1/20 0.47
NAMPT P43490 3/20 0.47
CHRM3 P20309 1/20 0.46
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
KAT6A Q92794 1/20 0.45
BRD4 O60885 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23352053 0.91 SENP1 (0.54) SENP1SENP2SENP5AURKARPS6KB1
SCHEMBL10160157 0.89 SENP1 (0.55) SENP1SENP2SENP5AURKARPS6KB1
SCHEMBL13622966 0.85 PTGS1 (0.55) PRMT5WDR77NAMPTKAT6AHDAC3
SCHEMBL13623004 0.83 SENP5 (0.54) SENP1SENP2SENP5LMNAALDH1A1
SCHEMBL306845 0.83 ROCK2 (0.60) SENP1SENP2SENP5LMNANR1H4
SCHEMBL13622713 0.82 AURKA (0.48) AURKARPS6KB1HDAC3HDAC1HDAC2
SCHEMBL1023993 0.82 SENP1 (0.58) SENP1SENP2SENP5NAMPTCHRM3
SCHEMBL13623115 0.81 AURKA (0.53) AURKARPS6KB1BRD4HDAC3HDAC1
SCHEMBL16527267 0.81 AURKA (0.54) SENP1SENP2SENP5AURKARPS6KB1
SCHEMBL31710947 0.81 AURKA (0.54) SENP1SENP2SENP5AURKARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SENP1 2867/4885SENP2 3357/4885SENP5 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.